Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22762259 | 0.83 | ALDH1A1 (0.44) | CA1CA2CA9IDO1ALDH1A1 | |
| SCHEMBL92354 | 0.83 | CA1 (0.44) | CA1CA2CA9IDO1ALDH1A1 | |
| SCHEMBL4449191 | 0.83 | CA1 (0.44) | CA1CA2CA9IDO1ALDH1A1 | |
| SCHEMBL6268780 | 0.82 | CA1 (0.44) | CA1CA2CA9TDP1IDO1 | |
| SCHEMBL17986293 | 0.80 | TAAR1 (0.42) | TSHR | |
| SCHEMBL11022222 | 0.80 | CA1 (0.43) | CA1CA2CA9TDP1IDO1 | |
| SCHEMBL7107594 | 0.80 | CA2 (0.56) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL3891204 | 0.79 | CA1 (0.41) | CA1CA2CA9IDO1ALDH1A1 | |
| SCHEMBL3959570 | 0.79 | CA1 (0.41) | CA1CA2CA9IDO1ALDH1A1 | |
| SCHEMBL10228461 | 0.79 | CA1 (0.41) | CA1CA2CA9IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5166218-A | Antilipemic agents or antiglycemic agents | HOFFMANN-LA ROCHE INC. (US) | 1992-11-24 | — | — | US | claimed |
| EP-0140243-B1 | PHENOXYPROPANOL AMINES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-11-09 | — | — | EP | claimed |
| US-4743604-A | ANTIBESITY, ANTIDIABETIC, FEEDS | HOFFMANN-LA ROCHE INC. (US) | 1988-05-10 | — | — | US | claimed |
| CN-114488688-A | Liquid crystal display element, method for producing same, and radiation-sensitive resin composition | JSR株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20110281040-A1 | LIQUID CRYSTAL DISPLAY ELEMENT, POSITIVE TYPE RADIATION SENSITIVE COMPOSITION, INTERLAYER INSULATING FILM FOR LIQUID CRYSTAL DISPLAY ELEMENT, AND FORMATION METHOD THEREOF | JSR CORPORATION (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7749678-B2 | contains sulfonium compound; improved line edge roughness and pattern profile, and contrast of sensitivity and dissolution in extreme ultraviolet exposure | FUJIFILM CORPORATION (JP) | 2010-07-06 | — | — | US | disclosed |
| EP-0201033-A2 | A method for processing silver halide color photographic materials | KONICA CORPORATION (JP) | 1986-11-12 | — | — | EP | disclosed |
| EP-0200206-A2 | Silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1986-11-05 | — | — | EP | disclosed |
| EP-0199351-A2 | Silver halide photographic material | KONICA CORPORATION (JP) | 1986-10-29 | — | — | EP | disclosed |
| EP-0199604-A2 | Processing method for light-sensitive silver halide color photographic material | KONICA CORPORATION (JP) | 1986-10-29 | — | — | EP | disclosed |
| EP-0187521-A2 | Light-sensitive silver halide photographic material | KONICA CORPORATION (JP) | 1986-07-16 | — | — | EP | disclosed |
| EP-0185506-A2 | Light-sensitive silver halide photographic material | KONICA CORPORATION (JP) | 1986-06-25 | — | — | EP | disclosed |
| EP-0182486-A1 | Silver halide color photographic material | KONICA CORPORATION (JP) | 1986-05-28 | — | — | EP | disclosed |
| EP-0178794-A1 | Silver halide color photographic material | KONICA CORPORATION (JP) | 1986-04-23 | — | — | EP | disclosed |
| EP-0178165-A1 | Silver halide color photographic material | KONICA CORPORATION (JP) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | CA1 2592/4885CA2 254/4885CA9 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.